Stock Events

Stock Events

Hillstream BioPharma 

$0.2370
37
+$0.01+5.66% Friday 21:59

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
2.73M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

29NovExpected
Q2 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q2 2023
Q3 2023
-0.18
-0.05
0.09
0.22
Expected EPS
-0.05
Actual EPS
0

Financials

-Profit Margin
Unprofitable
2020
2021
2022
0Revenue
-8.47MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap55.09B
Moderna, Inc. is a competitor because it also focuses on mRNA-based therapies, potentially overlapping with Tharimmune's immunotherapy approaches.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech SE operates in the field of mRNA technology for developing vaccines and therapeutics, directly competing with Tharimmune's technology platform.
Novavax
NVAX
Mkt Cap1.53B
Novavax, Inc. competes in the vaccine development space, particularly in the development of vaccines for infectious diseases, which may overlap with Tharimmune's focus areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a broad portfolio in vaccines and biopharmaceuticals, making it a competitor in various therapeutic areas that Tharimmune may target.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is involved in the development of antiviral drugs and other treatments that could compete with Tharimmune's immunotherapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is known for its work in immunology and infectious diseases, areas that Tharimmune may also be exploring.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a diverse biopharmaceutical portfolio, including treatments for cancer and other diseases, potentially competing with Tharimmune's research and development.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson operates in various healthcare sectors, including pharmaceuticals with a focus on immunology, making it a competitor to Tharimmune.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. has a strong presence in the development of vaccines and cancer therapies, areas that may intersect with Tharimmune's interests.
Sanofi
SNY
Mkt Cap107.39B
Sanofi is involved in the development of vaccines and treatments for immune system diseases, competing with Tharimmune in the immunotherapy space.

About

Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH3215 and TH0059, which are designed to address a variety of solid tumors; and TH1940, specifically targeting programmed cell death protein 1 (PD-1). Furthermore, the company has entered into a research collaboration and product license agreement with Minotaur Therapeutics, Inc. to develop proprietary targeted biologics. Originally incorporated in 2017 as Hillstream BioPharma, Inc., the company rebranded to Tharimmune, Inc. in September 2023 and maintains its headquarters in Bridgewater, New Jersey.
Show more...
CEO
Mr. Mark Wendland
Employees
2
Country
United States
ISIN
US4327051011

Listings

MX
MX
CNTN.MX
BOATS
BOATS
THAR.BOATS
XNAS
US
CNTN

0 Comments

Share your thoughts

FAQ

What is Hillstream BioPharma stock price today?▼
The current price of HILS is $0.24 USD — it has increased by +5.66% in the past 24 hours. Watch Hillstream BioPharma stock price performance more closely on the chart.
What is Hillstream BioPharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Hillstream BioPharma stocks are traded under the ticker HILS.
What is Hillstream BioPharma market cap?▼
Today Hillstream BioPharma has the market capitalization of 2.73M
What were Hillstream BioPharma earnings last quarter?▼
HILS earnings for the last quarter are 0 USD per share, whereas the estimation was -0.05 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Hillstream BioPharma revenue for the last year?▼
Hillstream BioPharma revenue for the last year amounts to 0 USD.
What is Hillstream BioPharma net income for the last year?▼
HILS net income for the last year is -8.47M USD.
How many employees does Hillstream BioPharma have?▼
As of September 04, 2026, the company has 2 employees.
In which sector is Hillstream BioPharma located?▼
Hillstream BioPharma operates in the Health & Wellness sector.
When did Hillstream BioPharma complete a stock split?▼
Hillstream BioPharma has not had any recent stock splits.
Where is Hillstream BioPharma headquartered?▼
Hillstream BioPharma is headquartered in Red Bank, United States.